Product Description: Milademetan (DS-3032) is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) induces G1 cell cycle arrest, senescence and apoptosis[1][2].
Applications: Cancer-programmed cell death
Formula: C30H34Cl2FN5O4
References: [1]ARYL SULFONOHYDRAZIDES. WO 2017069289 A1./[2]M.M. Gounder, et al. Milademetan, an oral MDM2 inhibitor, in well-differentiated/dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas. European Journal of Cancer 138S2 (2020) S1–S62./[3]Li, Yangbing, et al. Development of novel PROTAC Small-Molecule Degraders of MDM2 Protein and Peptidomimetic Inhibitors Targeting WDR5-MLL1 Protein-Protein Interaction./[4]Viktor Arnhold, et al. Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma. ncotarget. 2018 Jan 5; 9(2): 2304–2319.
CAS Number: 1398568-47-2
Molecular Weight: 618.53
Compound Purity: 98.77
Research Area: Cancer
Solubility: DMSO : 16.67 mg/mL (ultrasonic)
Target: Apoptosis;E1/E2/E3 Enzyme;MDM-2/p53
Deutsch
English
